4LN2 Stock Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Capricor Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.87 |
| 52 Week High | US$7.13 |
| 52 Week Low | US$2.50 |
| Beta | 4.04 |
| 1 Month Change | -20.51% |
| 3 Month Change | 32.74% |
| 1 Year Change | 45.22% |
| 3 Year Change | 55.93% |
| 5 Year Change | 34.76% |
| Change since IPO | -51.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4LN2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.2% | 1.8% | -1.2% |
| 1Y | 45.2% | -19.8% | 1.8% |
Return vs Industry: 4LN2 exceeded the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: 4LN2 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 4LN2 volatility | |
|---|---|
| 4LN2 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4LN2's share price has been volatile over the past 3 months.
Volatility Over Time: 4LN2's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 102 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc. Fundamentals Summary
| 4LN2 fundamental statistics | |
|---|---|
| Market cap | €155.61m |
| Earnings (TTM) | -€20.89m |
| Revenue (TTM) | €23.60m |
6.6x
P/S Ratio-7.4x
P/E RatioIs 4LN2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4LN2 income statement (TTM) | |
|---|---|
| Revenue | US$25.18m |
| Cost of Revenue | US$36.45m |
| Gross Profit | -US$11.27m |
| Other Expenses | US$11.02m |
| Earnings | -US$22.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | -44.76% |
| Net Profit Margin | -88.52% |
| Debt/Equity Ratio | 0% |
How did 4LN2 perform over the long term?
See historical performance and comparison